Beam Therapeutics (BEAM) News Today $30.43 -2.71 (-8.18%) Closing price 04:00 PM EasternExtended Trading$30.60 +0.18 (+0.58%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Cathie Wood’s ARK Investment buys 171K shares of Beam Therapeutics todayFebruary 21 at 5:58 AM | markets.businessinsider.comC2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Takes $330,000 Position in Beam Therapeutics Inc. (NASDAQ:BEAM)C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 13,28February 21 at 4:19 AM | marketbeat.comNew proton beam therapy precisely targets and destroys cancer cellsFebruary 20 at 12:20 PM | msn.comBeam Therapeutics (BEAM) to Release Earnings on TuesdayBeam Therapeutics (NASDAQ:BEAM) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18 at 5:34 AM | marketbeat.comBaillie Gifford & Co. Decreases Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM)Baillie Gifford & Co. decreased its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 13.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 308,236 shares of the company's stock after sFebruary 18 at 4:49 AM | marketbeat.comShort Interest in Beam Therapeutics Inc. (NASDAQ:BEAM) Drops By 7.1%Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) was the recipient of a large decrease in short interest in January. As of January 31st, there was short interest totalling 10,020,000 shares, a decrease of 7.1% from the January 15th total of 10,790,000 shares. Based on an average daily trading volume, of 1,150,000 shares, the days-to-cover ratio is presently 8.7 days.February 17, 2025 | marketbeat.comPeregrine Investment Management Inc. Makes New $3.93 Million Investment in Beam Therapeutics Inc. (NASDAQ:BEAM)Peregrine Investment Management Inc. bought a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 158,550 shares of the company's stock,February 16, 2025 | marketbeat.comBrokerages Set Beam Therapeutics Inc. (NASDAQ:BEAM) Target Price at $47.67February 16, 2025 | americanbankingnews.comBeam Therapeutics (NASDAQ:BEAM) Shares Up 17.9% - Here's WhyBeam Therapeutics (NASDAQ:BEAM) Trading 17.9% Higher - Should You Buy?February 15, 2025 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Recommendation of "Buy" by AnalystsShares of Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) have been given a consensus rating of "Buy" by the twelve analysts that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation, eight have given a buy recommendatiFebruary 13, 2025 | marketbeat.comBMO Capital maintains Outperform on Beam Therapeutics stockFebruary 11, 2025 | msn.comBeam Therapeutics Inc. (NASDAQ:BEAM) Shares Purchased by Sumitomo Mitsui Trust Group Inc.Sumitomo Mitsui Trust Group Inc. raised its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 11.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 3,957,611 shares of the company's stock after acqFebruary 9, 2025 | marketbeat.comBeam Therapeutics (NASDAQ:BEAM) Shares Up 8% - Still a Buy?Beam Therapeutics (NASDAQ:BEAM) Trading 8% Higher - Should You Buy?February 5, 2025 | marketbeat.comFY2026 Earnings Estimate for BEAM Issued By HC WainwrightBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Analysts at HC Wainwright issued their FY2026 earnings estimates for shares of Beam Therapeutics in a research report issued to clients and investors on Monday, February 3rd. HC Wainwright analyst P. Trucchio anticipates that the company will pFebruary 5, 2025 | marketbeat.comBrokers Set Expectations for BEAM Q1 EarningsBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 EPS estimates for Beam Therapeutics in a research note issued on Monday, February 3rd. HC Wainwright analyst P. Trucchio expects that the company will post earnings per share of (February 4, 2025 | marketbeat.comH.C. Wainwright maintains $80 target on Beam Therapeutics stockFebruary 4, 2025 | msn.comBeam Therapeutics Inc. (NASDAQ:BEAM) CEO Sells $802,500.00 in StockBeam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) CEO John M. Evans sold 30,000 shares of Beam Therapeutics stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $26.75, for a total value of $802,500.00. Following the completion of the sale, the chief executive officer now directly owns 908,659 shares of the company's stock, valued at $24,306,628.25. The trade was a 3.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.February 3, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Beam Therapeutics (NASDAQ:BEAM)HC Wainwright reaffirmed a "buy" rating and set a $80.00 price target on shares of Beam Therapeutics in a research report on Monday.February 3, 2025 | marketbeat.comDemystifying Beam Therapeutics: Insights From 4 Analyst ReviewsJanuary 31, 2025 | benzinga.comInvestors in Beam Therapeutics (NASDAQ:BEAM) from three years ago are still down 55%, even after 3.8% gain this past weekJanuary 31, 2025 | finance.yahoo.comCantor Fitzgerald Issues Positive Forecast for BEAM EarningsBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2024 earnings estimates for shares of Beam Therapeutics in a research report issued on Wednesday, January 29th. Cantor Fitzgerald analyst R. Bienkowski now anticipates that the company willJanuary 31, 2025 | marketbeat.comCantor Fitzgerald Upgrades Beam Therapeutics (BEAM)January 30, 2025 | msn.comBeam Therapeutics to Participate in Guggenheim SMID Cap Biotech ConferenceJanuary 30, 2025 | globenewswire.comBeam Therapeutics upgraded to Overweight from Neutral at Cantor FitzgeraldJanuary 30, 2025 | markets.businessinsider.comBeam Therapeutics (NASDAQ:BEAM) Shares Gap Up - Here's What HappenedBeam Therapeutics (NASDAQ:BEAM) Shares Gap Up - Here's What HappenedJanuary 29, 2025 | marketbeat.comBeam Therapeutics (NASDAQ:BEAM) Raised to "Overweight" at Cantor FitzgeraldCantor Fitzgerald raised Beam Therapeutics from a "neutral" rating to an "overweight" rating in a report on Wednesday.January 29, 2025 | marketbeat.comPositive Report for Beam Therapeutics (BEAM) from BernsteinJanuary 24, 2025 | markets.businessinsider.comFY2024 Earnings Forecast for BEAM Issued By Leerink PartnrsBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Investment analysts at Leerink Partnrs upped their FY2024 earnings per share estimates for shares of Beam Therapeutics in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that tJanuary 24, 2025 | marketbeat.comBeam Therapeutics to encore data from BEACON Phase 1/2 trial of Beam-101January 24, 2025 | markets.businessinsider.comBeam Therapeutics to present updated BEAM-101 trial dataJanuary 23, 2025 | msn.comCantor Fitzgerald Forecasts BEAM FY2025 EarningsBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Beam Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski expects that the company will post earnings of ($3.48)January 23, 2025 | marketbeat.comBeam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTRJanuary 23, 2025 | globenewswire.comBeam Therapeutics: Too Expensive For Me, But Watch For Important CatalystsJanuary 22, 2025 | seekingalpha.comAvanza Fonder AB Invests $1.25 Million in Beam Therapeutics Inc. (NASDAQ:BEAM)Avanza Fonder AB purchased a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 50,285 shares of the company's stock, valued at apJanuary 20, 2025 | marketbeat.comCT approves $80M Danbury cancer center using ‘new and evolving’ proton therapy after 5-year battleJanuary 19, 2025 | msn.comBeam Therapeutics Inc. (NASDAQ:BEAM) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the twelve analysts that are currently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, seven have assigneJanuary 19, 2025 | marketbeat.comState-of-the-art proton beam cancer treatment is coming to Connecticut for the first timeJanuary 19, 2025 | msn.comBeam Therapeutics' SWOT analysis: gene editing pioneer's stock faces crucial clinical milestonesJanuary 16, 2025 | msn.comBeam Therapeutics (NASDAQ:BEAM) Trading Down 8% - Here's What HappenedBeam Therapeutics (NASDAQ:BEAM) Shares Down 8% - Should You Sell?January 15, 2025 | marketbeat.comBernstein Keeps Their Buy Rating on Beam Therapeutics (BEAM)January 15, 2025 | markets.businessinsider.comBeam Therapeutics (BEAM) Gets a Hold from Bank of America SecuritiesJanuary 15, 2025 | markets.businessinsider.comBeam Therapeutics: Strong Pipeline and Strategic Global Expansion Justify Buy RatingJanuary 14, 2025 | markets.businessinsider.comBeam Therapeutics Positioned for Growth: Strong Pipeline and Financial Resilience Drive Buy RatingJanuary 14, 2025 | markets.businessinsider.comBeam Therapeutics (NASDAQ:BEAM) Given Outperform Rating at WedbushWedbush reiterated an "outperform" rating and issued a $57.00 target price on shares of Beam Therapeutics in a research note on Monday.January 13, 2025 | marketbeat.comBeam Therapeutics outlines key 2025 anticipated catalystsJanuary 13, 2025 | markets.businessinsider.comBeam Therapeutics sees cash runway into 2027January 13, 2025 | markets.businessinsider.comBeam Therapeutics (NASDAQ:BEAM) Stock Price Down 8% - What's Next?Beam Therapeutics (NASDAQ:BEAM) Trading Down 8% - Here's What HappenedJanuary 13, 2025 | marketbeat.comBeam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated CatalystsJanuary 13, 2025 | globenewswire.comBeam Therapeutics Inc. (NASDAQ:BEAM) Shares Sold by JPMorgan Chase & Co.JPMorgan Chase & Co. lowered its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 18.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 639,238 shares of the company's stock after seJanuary 11, 2025 | marketbeat.comPrecision gene editing could prevent vision loss from Stargardt diseaseJanuary 10, 2025 | msn.com Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address BEAM Media Mentions By Week BEAM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BEAM News Sentiment▼0.630.60▲Average Medical News Sentiment BEAM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BEAM Articles This Week▼96▲BEAM Articles Average Week Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PCVX News SRPT News QGEN News ASND News ROIV News RVMD News LEGN News BBIO News AXSM News BPMC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BEAM) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
